tiprankstipranks
Trending News
More News >
Apollomics (APLM)
NASDAQ:APLM
US Market
Advertisement

Apollomics (APLM) AI Stock Analysis

Compare
282 Followers

Top Page

APLM

Apollomics

(NASDAQ:APLM)

Rating:42Neutral
Price Target:
Apollomics' stock score is primarily impacted by its financial instability, characterized by persistent losses and high leverage. While there are slight technical indicators of improvement, the negative P/E ratio and absence of dividends present valuation challenges. Overall, the stock's speculative nature and financial concerns result in a low score.

Apollomics (APLM) vs. SPDR S&P 500 ETF (SPY)

Apollomics Business Overview & Revenue Model

Company DescriptionApollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
How the Company Makes MoneyApollomics primarily generates revenue through the development and commercialization of its oncology drug candidates. The company's revenue streams include milestone payments and royalties from partnerships with other pharmaceutical companies. Additionally, Apollomics may generate income from licensing its proprietary technologies and intellectual property to third parties. Significant partnerships with larger pharmaceutical firms can provide funding for drug development and potential co-marketing opportunities, contributing to its earnings.

Apollomics Financial Statement Overview

Summary
Apollomics faces significant financial challenges with persistent losses, high leverage, and negative cash flows. Though there are slight improvements in equity and revenue growth, profitability and cash flow generation remain critical areas for improvement.
Income Statement
25
Negative
Apollomics shows a consistent pattern of negative profitability with significant net losses over multiple years. The company reported a negative gross profit margin and declining EBIT and EBITDA margins. While there is revenue growth from 2022 to 2023, the overall financial health in terms of profitability remains weak.
Balance Sheet
30
Negative
The balance sheet indicates a high level of liabilities relative to equity, resulting in a negative debt-to-equity ratio historically. Although the equity improved to positive in 2023, which is a positive sign, the overall leverage remains a concern. The equity ratio is relatively low for the biotechnology industry, suggesting potential financial instability.
Cash Flow
35
Negative
Cash flows are challenging, with negative operating cash flow and free cash flow across the years. There was a slight improvement in 2023's free cash flow growth rate, but the operating cash flow to net income ratio indicates inefficiencies in turning income into cash. Cash flow management remains a crucial area for improvement.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.27M0.00821.00K323.00K2.00K1.84M
Gross Profit2.27M0.00127.00K-452.00K-679.00K1.23M
EBITDA-53.02M-53.42M-171.75M-239.94M-94.03M-74.22M
Net Income-57.11M-53.86M-172.60M-240.81M-94.80M-74.82M
Balance Sheet
Total Assets34.57M13.10M55.39M76.47M123.44M169.94M
Cash, Cash Equivalents and Short-Term Investments25.93M9.77M37.82M54.61M94.48M154.39M
Total Debt4.72M966.00K4.66M991.00K1.04M1.51M
Total Liabilities13.77M8.23M14.15M524.60M336.30M297.87M
Stockholders Equity20.81M4.86M41.23M-448.12M-212.86M-127.93M
Cash Flow
Free Cash Flow-34.82M-28.77M-43.22M-43.19M-50.86M-45.83M
Operating Cash Flow-34.80M-28.74M-43.21M-42.82M-43.31M-35.68M
Investing Cash Flow27.35M5.98M21.36M29.05M-38.95M2.33M
Financing Cash Flow8.10M468.00K21.23M-294.00K-1.64M125.51M

Apollomics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price6.15
Price Trends
50DMA
6.20
Negative
100DMA
6.51
Negative
200DMA
8.41
Negative
Market Momentum
MACD
<0.01
Negative
RSI
49.17
Neutral
STOCH
38.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APLM, the sentiment is Negative. The current price of 6.15 is below the 20-day moving average (MA) of 6.23, below the 50-day MA of 6.20, and below the 200-day MA of 8.41, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 49.17 is Neutral, neither overbought nor oversold. The STOCH value of 38.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APLM.

Apollomics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$17.07B6.10-7.44%2.88%11.55%-28.15%
42
Neutral
$6.79M-233.67%-1786.46%
39
Underperform
$4.54M-437.73%57.83%
34
Underperform
$7.32M-590.37%-73095.97%
33
Underperform
$14.43M-339.64%-75.88%
27
Underperform
$9.40M-342.99%99.64%
$3.13M-154.54%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
APLM
Apollomics
6.15
-16.05
-72.30%
SNGX
Soligenix
1.39
-3.14
-69.32%
MTVA
MetaVia
0.70
-3.45
-83.13%
RNAZ
TransCode Therapeutics
11.00
-262.13
-95.97%
SLXN
Silexion Therapeutics
0.84
-104.37
-99.20%
LIPO
Lipella Pharmaceuticals, Inc.
0.72
-2.51
-77.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025